Roche said Wednesday that its experimental cancer immunotherapy directed against a target called TIGIT suffered its second consecutive setback, failing this time to slow tumor growth in a large study involving the most common type of lung cancer.
The study’s disappointing outcome is a significant blow to the Swiss pharma giant’s effort to develop the antibody treatment called tiragolumab — the most important cancer drug in its research pipeline, and a linchpin in its strategy to greatly expand the pool of patients who might benefit from treatments that work by activating the immune system to find and kill tumors.
Last month, Roche said tiragolumab showed no benefit in a large study involving patients with a less common but aggressive type of lung cancer.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
